SciSparc Ltd. (SPRC): VRIO Analysis [Mar-2026 Updated]

Is SciSparc Ltd. (SPRC) truly positioned for sustainable success? Our rigorous VRIO analysis cuts straight to the core, examining whether its resources are Valuable, Rare, Inimitable, and Organized to capture a lasting competitive edge. Discover the definitive verdict on SciSparc Ltd. (SPRC)'s strategic strengths and weaknesses immediately below.

SciSparc Ltd. (SPRC) - VRIO Analysis: 1. Acquired MUSE™ Endoscopic System IP Portfolio (Nov 2025)

You’re looking at a major strategic pivot for SciSparc Ltd., moving beyond its core pharmaceutical focus into the medical device space with this IP grab. The key takeaway here is that the value is high-potential, but the cost - in terms of dilution - is immediate and substantial.

Value: Entering a Multi-Billion Dollar Niche

This acquisition immediately positions SciSparc to enter the global Gastroesophageal Reflux Disease (GERD) device market. That market was valued at about $2.5 billion in 2024 and is expected to grow to $3.03 billion by 2030. The MUSE™ system, designed for minimally invasive transoral fundoplication, targets a specific, high-value treatment area. Honestly, getting a full IP portfolio ready for commercialization is a huge shortcut past years of R&D.

• Targets GERD device market projected to hit $3.03 billion by 2030.
• Leverages Xylo’s prior success: a $3 million upfront payment from a 2019 licensing deal in Greater China.

Rarity: A Large Asset for a Small Player

For a company with a market capitalization around $2.82 million as of December 5, 2025, acquiring a complete, approved IP portfolio for a system like MUSE is quite rare. Most companies at this stage are either developing early-stage assets or acquiring smaller pieces of technology. This is a full package of patents and trademarks. It’s a big swing for a micro-cap firm.

Imitability: Legal Moat, Execution Risk

The patents and trademarks secured offer a strong legal barrier against direct copying, which is the definition of inimitability in this context. Still, the underlying technology’s commercial success isn't guaranteed by patents alone. Competitors can develop workarounds or superior next-generation devices, but they face a legal hurdle to copy this specific system. What this estimate hides is the time it takes to get regulatory approval in new territories like North America and Europe.

Organization: Commitment vs. Dilution

SciSparc is definitely organizing to exploit this by committing a large chunk of equity. The deal requires issuing ordinary shares representing 19.99% of the company’s outstanding share capital upon closing. This shows serious commitment to integrating this asset class, but it’s a massive dilution event for existing shareholders. The plan is to replicate Xylo’s licensing model across North America, Europe, and Latin America.

Here’s the quick math on the payment structure:

Competitive Advantage Evaluation

The advantage is potentially sustained, but only if the execution risk is managed. If they successfully license this IP into the targeted markets, the legal protection of the patents should translate into a long-term revenue stream. If they fail to secure strong distribution partners, the advantage evaporates quickly.

• Potential Advantage: Sustained (if commercialization succeeds)
• Current Status: Temporary Advantage (due to high execution risk)
• Key Action: Finalize definitive agreements and secure regional distribution partners by Q2 2026.

Finance: draft pro-forma capitalization table showing the impact of the 19.99% share issuance by Wednesday.

SciSparc Ltd. (SPRC) - VRIO Analysis: 2. CNS/Neuro-Therapeutic Drug Pipeline (via NeuroThera Labs Inc.)

SciSparc manages its CNS pipeline through its majority-owned subsidiary, NeuroThera Labs Inc., in which SciSparc holds approximately 75%, potentially rising to 84% upon fulfillment of pre-determined milestones.

The pipeline holds drug candidates based on THC and/or non-psychoactive CBD, with the transferred assets valued at approximately US$11.6 million in the transaction that established NeuroThera Labs.

The enterprise value of NeuroThera Labs at the time of the asset transfer was approximately US$3.3 million, including approximately US$1.0 million in cash.

The specific combination of cannabinoid-based assets targeting TS, Alzheimer's agitation, ASD, status epilepticus, and pain within one controlled entity is unique to SciSparc's current structure.

Clinical trial data, such as the 23% reduction in agitation for SCI-110, and specific regulatory milestones, like the FDA IND approval for the Phase IIb TS trial, are difficult to replicate quickly.

The core pharma work is managed through the majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX), which received the assets valued at US$11.6 million.

• SciSparc committed CAD 1,000,000 (approximately US$716,000) to NeuroThera via an unsecured convertible note maturing October 22, 2027.
• SciSparc received 63,300,000 common shares of Neurothera in the transaction.

The advantage is temporary, contingent upon positive outcomes in the ongoing and planned clinical trials for SCI-110 and SCI-210.

SciSparc Ltd. (SPRC) - VRIO Analysis: 3. Scientific Advisory Board led by Professor Raphael Mechoulam

Value

Board expertise underpins R&D strategy, attracting investment and talent.

Rarity

World-class, award-winning chair is exceptionally rare for a smaller-cap entity.

• Professor Mechoulam is globally acknowledged as the father of cannabinoid research.
• He was among the first to complete the total synthesis of major plant cannabinoids, including THC, CBD, and CBG.

Imitability

Personal reputation and established networks are nearly impossible to replicate quickly.

Organization

Guidance is explicitly integrated into operations, evidenced by the product pipeline.

• SCI-160 utilizes the HU-433 agonist synthesized by Professor Mechoulam.
• CannAmide™ (PEA formulation) contains 400mg active pharmaceutical ingredient per dose and holds a product license from Health Canada.

Competitive Advantage

Sustained advantage derived from scientific gravitas attracting high-caliber partners and assets.

Company Research & Development for the period ending December 31, 2024, was reported as -1.7m USD.

SciSparc Ltd. (SPRC) - VRIO Analysis: 4. Near-Zero Debt Capital Structure (FY 2025)

The analysis below primarily utilizes the latest reported annual financial data available, specifically for Fiscal Year 2024 (ending December 31, 2024), to substantiate the near-zero debt structure premise.

Value

The company maintained a low financial leverage position, evidenced by a reported Debt / Equity Ratio of approximately 0.01 for Fiscal Year 2024. This structure implies minimal fixed financing obligations, reducing vulnerability during operational or market downturns.

Rarity

For a clinical-stage biotechnology entity, a Debt-to-Equity ratio near 0.01 is uncommon, as this stage often necessitates debt financing to bridge development capital gaps. The reported Short-Term Debt was $0 for FY 2024, FY 2023, FY 2022, FY 2021, and FY 2020.

Imitability

The near-zero debt posture is primarily a result of strategic financing decisions, specifically favoring equity issuance over debt instruments. This is imitable by a competitor only through a conscious, sustained strategic choice to avoid leverage.

Organization

The organization has consistently prioritized equity financing, resulting in a clean balance sheet profile. Key financial figures from the latest reported full fiscal year (FY 2024) illustrate this structure:

• Total Shareholder Equity (FY 2024): $8.94 million
• Total Liabilities (FY 2024): $1.40 million (Total Current Liabilities)
• Total Assets (FY 2024): $10.35 million

The organization's structure is further detailed in the following comparative table:

Competitive Advantage

The current advantage is Temporary. While the lack of debt provides a significant financial buffer against immediate liquidity or solvency shocks, the company retains the strategic option to assume debt financing in the future, which would alter this competitive profile.

SciSparc Ltd. (SPRC) - VRIO Analysis: 5. Nasdaq Listing and Market Visibility (SPRC)

Value: Maintaining a listing on the Nasdaq Capital Market provides access to US capital markets and a level of institutional visibility that private or OTC-listed peers lack. The company's market capitalization, as recently reported, was approximately $2.82 million as of December 5, 2025. The listing allows trading on an exchange where the Average Volume (20 Days) was reported as 3,361,028 shares.

Rarity: Listing on a major US exchange is not rare, but it is a necessary threshold for many institutional investors. The company's authorized share capital remains at 75,000,000 Ordinary Shares.

Imitability: It requires meeting strict SEC and exchange requirements, which is a barrier to entry for smaller, non-compliant firms. The company previously faced non-compliance with Nasdaq Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share.

Organization: The recent 1-for-21 reverse share split in July 2025, reducing shares from 11,225,751 to approximately 534,600, shows the organization is actively managing governance to maintain this listing.

Competitive Advantage: Temporary, as compliance costs and market conditions can threaten delisting if not managed carefully. The company's current ratio stands at 5.36, indicating strong liquidity.

Key data points related to the Nasdaq listing structure and compliance efforts:

Organizational actions taken to maintain listing visibility:

• Received a 180-day extension from Nasdaq on January 14, 2025, with a deadline of July 14, 2025, to regain compliance with the minimum bid price rule.
• The reverse share split was approved by shareholders on October 23, 2024.
• Regained compliance with Nasdaq Listing Rule 5550(a)(2) on July 18, 2025, after the closing bid price was at or above $1.00 per share for 10 consecutive business days.

SciSparc Ltd. (SPRC) - VRIO Analysis: 6. Recent Strategic Divestiture (MitoCareX Sale, Oct 2025)

The divestiture of the majority-owned subsidiary MitoCareX Bio Ltd. to N2OFF, Inc. closed on October 23, 2025. SciSparc initially held a 52.73% ownership stake in MitoCareX.

Value:

The transaction provided an immediate cash infusion and a shift in strategic focus toward the CNS pipeline and the GERD IP.

Rarity:

The successful execution of a strategic divestiture to streamline operations is a singular event, not a recurring resource.

• The intended selling valuation represented a 47% increase from SciSparc's initial investment valuation of $3.4 million in MitoCareX.

Imitability:

The strategic choice to divest is generally imitable; however, the specific realized financial terms and timing relative to the October 2025 closing date are unique to SciSparc's circumstances.

Organization:

The completion of the transaction demonstrates organizational capability in executing complex M&A structures involving cash, equity exchange, and contingent consideration.

• The transaction involved SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri as 'Sellers'.
• The deal involved the transfer of MitoCareX's proprietary algorithm, MITOLINE™, and in vitro screening systems.

Competitive Advantage:

The advantage is Temporary; the immediate financial benefit is realized upon closing, requiring subsequent execution on the remaining core assets to sustain value creation.

SciSparc Ltd. (SPRC) - VRIO Analysis: 7. Quantum-Powered 3D Protein Modeling Initiative

The board of directors resolved to initiate the launch of the Initiative on September 16, 2025.

Value: The initiative targets the use of quantum computing concepts for 3D protein modeling to revolutionize AI drug discovery, potentially accelerating R&D timelines significantly.

Rarity: Integrating quantum-adjacent technology into early-stage drug discovery modeling is cutting-edge and rare outside of major tech/pharma collaborations.

Imitability: The specific algorithms and partnerships underpinning this initiative would be difficult to copy without deep technical know-how.

Organization: The company announced its resolve to launch this, indicating a strategic allocation of R&D budget toward this future-facing technology. The announcement led to a premarket stock surge of 45.5% on one report date. The company plans to form a dedicated research team and incorporate a new wholly owned Israeli subsidiary to operate the Initiative.

Analyst projections include sales growth of 17% for the current year and a projected EPS of $60.86.

Competitive Advantage: Sustained, if they can establish an early lead in applying this novel computational method to their therapeutic targets.

• The initiative focuses on developing quantum-enabled tools to:
• Accurately predict how proteins fold into their 3D shapes.
• Model how proteins interact with potential drugs (protein-ligand interactions).
• Accelerate the discovery of new drugs by providing highly precise predictions.

SciSparc Ltd. (SPRC) - VRIO Analysis: 8. High Gross Profit Potential from New IP

The transition to commercializing the MUSE™ intellectual property represents a potential shift in SciSparc’s financial profile, moving from high R&D expenditure toward device sales margins.

Value

While TTM Revenue ending September 2025 was only $1.31 million with a Gross Profit of $0.51 million, the MUSE™ IP acquisition is for a device market where margins are typically higher than early-stage drug development, offering a clearer path to positive gross margins. The GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.

Rarity

The potential for high margins on a near-term product line contrasts sharply with the negative operating income of -$7.44 million TTM ending September 2025. The company's TTM R&D Expenses were $1.9 million against TTM Revenue of $1.31 million.

Imitability

The specific market positioning and cost structure of the MUSE™ system are protected by the acquired IP, which includes patents and trademarks. The technology leverages Xylo's prior commercialization success, which included securing a $3 million upfront payment in China in 2019.

Organization

The organization must now pivot resources from pure R&D burn to commercialization planning for this device asset. The current organizational structure is reflected in its TTM Selling, General & Admin expenses of $6.04 million. The acquisition itself is structured to avoid immediate cash outflow, involving the issuance of ordinary shares representing 19.99% of the issued and outstanding share capital upon closing.

Competitive Advantage

Temporary, as market entry will invite competition, but the initial IP position grants a head start. The GERD device market includes established competitors such as Olympus Corporation and Medtronic Plc.

Key Financial and Market Metrics:

• TTM Revenue (ending Sep '25): $1.31 million
• TTM Gross Profit (ending Sep '25): $0.51 million
• TTM Operating Income (ending Sep '25): -$7.44 million
• Projected GERD Market CAGR (2025-2030): 3.24%
• Acquisition Consideration: Issuance of shares equal to 19.99% of outstanding capital

Comparative Financial and Market Data:

SciSparc Ltd. (SPRC) - VRIO Analysis: 9. Operational Efficiency in Managing R&D Burn

Value: Despite a net loss, understanding the cost structure is key; the organization needs to ensure spending is on future growth. For the TTM ending Sep '25, Operating Expenses were \$7.94 million, with R&D at \$1.9 million and SG&A at \$6.04 million.

Rarity: The ability to maintain a relatively controlled R&D spend compared to SG&A (which is high relative to revenue) is a point of scrutiny, but the overall structure shows where the cash is going.

Imitability: Cost structures are imitable, but the specific historical spending patterns are unique to SciSparc's operational history.

Organization: The organization is organized to spend heavily on operations to support the pipeline, but the high SG&A relative to revenue (TTM Sep '25) suggests overhead management is an area for improvement.

Competitive Advantage: None, as high operating expenses relative to low revenue (\$1.31 million TTM) indicate a reliance on external funding, which is a vulnerability.

The following table summarizes key financial metrics for the Trailing Twelve Months (TTM) ending September '25, in millions of USD, illustrating the operational cost structure:

Finance: The expected share issuance for the Xylo IP deal involves issuing ordinary shares representing 19.99% of SciSparc's outstanding share capital upon closing, or alternatively, issuing pre-funded warrants to purchase ordinary shares. This transaction is intended to support the commercialization strategy for the MUSE system in North America, Europe, and Latin America, building on Xylo's prior licensing agreement which secured an upfront payment of \$3 million.

Key external market data relevant to the acquired IP:

• Global GERD device market valuation in 2024: \$2.5 billion.
• Projected global GERD device market valuation by 2030: \$3.03 billion.
• Projected Compound Annual Growth Rate (CAGR) for the market (2025 to 2030): 3.24%.

A definitive 13-week cash flow projection incorporating the expected share issuance by Friday cannot be provided without specific weekly cash flow estimates or the closing date of the definitive agreements. The projection would incorporate the non-cash consideration (share issuance) and potential cash proceeds if pre-funded warrants are issued, alongside existing cash burn rates derived from the TTM operating losses.